Shots:
- Health Canada has approved Opzelura cream 1.5% for the treatment of mild to mod. AD in children (≥2yrs.), when other topical therapies are ineffective or unsuitable
- Approval was based on the P-III (TRuE-AD3) trial, evaluating Opzelura (BID) vs vehicle in over 300 children (≥2 to <12yrs.) with AD
- Trial met its 1EP with more pts achieving IGA-TS at Wk 8, plus the proportion with IGA 0/1 remained high during Wk. 8 through 52 in those continuing study & applied Opzelura on an intermittent, as-needed basis; data published in The JAAD
Ref: Newswire.CA | Image: Incyte | Press Release
Related News:- Incyte Reports the US FDA’s sNDA Approval of Opzelura (Ruxolitinib) for Atopic Dermatitis (AD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
